文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants.

作者信息

Wang Yu, Zhao Danyang, Liu Xinbing, Chen Xubo, Xiao Wenying, Feng Liuliu

机构信息

Department of Cardiology, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.

Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

J Med Virol. 2023 Jan;95(1):e28443. doi: 10.1002/jmv.28443.

DOI:10.1002/jmv.28443
PMID:36579782
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9880690/
Abstract
摘要

相似文献

[1]
Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants.

J Med Virol. 2023-1

[2]
The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial.

Front Med (Lausanne). 2022-9-6

[3]
Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2.

Front Public Health. 2022

[4]
Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report.

Medicine (Baltimore). 2022-11-11

[5]
Association between immunity and viral shedding duration in non-severe SARS-CoV-2 Omicron variant-infected patients.

Front Public Health. 2022

[6]
Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.

J Virol. 2023-1-31

[7]
Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients.

Eur J Gastroenterol Hepatol. 2022-9-1

[8]
Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.

EBioMedicine. 2022-9

[9]
Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant.

Microbiol Spectr. 2022-10-26

[10]
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

MMWR Morb Mortal Wkly Rep. 2022-6-24

引用本文的文献

[1]
A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19.

Nat Commun. 2025-8-1

[2]
Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19.

BMC Infect Dis. 2025-5-14

[3]
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.

Commun Med (Lond). 2025-1-6

[4]
A multicenter randomized control trial: Point-of-care syndromic assessment versus standard testing in urgent care center patients with acute respiratory illness.

J Am Coll Emerg Physicians Open. 2024-10-23

[5]
A narrow ratio of nucleic acid to SARS-CoV-2 N-protein enables phase separation.

J Biol Chem. 2024-11

[6]
Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study.

Front Pharmacol. 2024-8-19

[7]
Clinical feature of omicron infection in children with inborn errors of immunity in China.

Front Immunol. 2024

[8]
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.

Infect Dis Ther. 2024-9

[9]
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.

BMC Infect Dis. 2024-6-18

[10]
A narrow ratio of nucleic acid to SARS-CoV-2 N-protein enables phase separation.

bioRxiv. 2024-4-11

本文引用的文献

[1]
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.

Lancet Infect Dis. 2022-9

[2]
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

MMWR Morb Mortal Wkly Rep. 2022-6-24

[3]
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.

Clin Infect Dis. 2023-2-8

[4]
Nirmatrelvir Plus Ritonavir: First Approval.

Drugs. 2022-4

[5]
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.

N Engl J Med. 2022-4-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索